Rucaparib phosphate

Rucaparib is a potent (Ki<5 nM) PARP1 inhibitor.1 Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.2 Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines.3 Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel3 and temozolamide.4 Ameliorates the cardiotoxicity of doxorubicin.5 Recently approved for human use by the FDA.